Get the Stockscreener App
0.9555
2.24%
-0.0219
After Hours:
.96
0.0045
+0.47%
Ocugen Inc stock is traded at $0.9555, with a volume of 13.26M.
It is down -2.24% in the last 24 hours and down -10.28% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.9774
Open:
$0.9739
24h Volume:
13.26M
Relative Volume:
1.91
Market Cap:
$324.02M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-4.1221
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
-6.32%
1M Performance:
-10.28%
6M Performance:
-48.90%
1Y Performance:
-47.79%
1-Day Range:
$0.9001
$0.9955
1-Week Range:
$0.9001
$1.12
52-Week Range:
$0.9001
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9555 | 324.02M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Canada
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
OCGN Stock Slips As Traders Focus On Weak Financials - StocksToTrade
OCGN Stock Slips As Weak Financials Weigh On Momentum - timothysykes.com
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts (OCGN) - Seeking Alpha
What's Happening With Ocugen Stock Thursday? - TradingView
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com India
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com Canada
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com UK
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com
OCGN Maintains Buy by HC Wainwright & Co. -- Price Target Lowered to $9.50 - GuruFocus
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay By Investing.com - Investing.com South Africa
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
An Ocugen (NASDAQ: OCGN) insider plans a stock sale; the exact size is detailed in an SEC notice - Stock Titan
OCGN Looks 32.9% Overvalued on GF Value™ Amid Phase 2/3 Trial Se - GuruFocus
Ocugen slips after Stargardt disease trial data (OCGN:NASDAQ) - Seeking Alpha
OCGN Stock Slides As Traders Focus On Cash Burn And Key Support - timothysykes.com
Ocugen doses first patient in phase 3 GA gene therapy trial - Glance by Eyes On Eyecare
Ocugen Announces US$40 Million Registered Direct Offering Priced at $2.00 Per Share - Minichart
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA - cgtlive.com
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Penny Stock Nears Major Gene Therapy Catalyst - Kalkine Media
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - Eyewire+
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Australia
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Nigeria
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com UK
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Doses First Patient in OCU410 Phase 3 Trial | OCGN Stock News - Stock Titan
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Yahoo Finance
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen to Present Modifier Gene Therapy Platform at Upcoming Investor and Industry Conferences in September 2026 - Quiver Quantitative
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls - Eastern Progress
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ocugen Inc Stock (OCGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
57,264 |
64,136 |
1,088,035 |
| Shankar Musunuri | Officer |
Sep 09 '26 |
Proposed Sale |
1.12 |
525,991 |
589,741 |
0 |
| Johnson-Greene Treerita Essali | Chief Financial Officer |
Jun 15 '26 |
Buy |
1.23 |
21,000 |
25,830 |
521,000 |
| Zhang Junge | Director |
Apr 01 '26 |
Option Exercise |
0.79 |
194,134 |
154,303 |
1,359,316 |
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):